Total Payments
$1.7M
2024 Payments
$218,942
Companies
55
Transactions
3,120
Medicare Patients
5,851
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$1.4M (82.5%)
Travel$143,757 (8.6%)
Consulting$91,109 (5.4%)
Food & Beverage$56,885 (3.4%)
Research$2,000 (0.1%)
Education$229.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $904,098 | 415 | 53.8% |
| Honoraria | $482,983 | 149 | 28.7% |
| Travel and Lodging | $143,757 | 601 | 8.6% |
| Consulting Fee | $91,109 | 34 | 5.4% |
| Food and Beverage | $56,885 | 1,908 | 3.4% |
| Unspecified | $2,000 | 1 | 0.1% |
| Education | $229.20 | 12 | 0.0% |
Payments by Type
General
$1.7M
3,119 transactions
Research
$2,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $404,290 | 639 | $0 (2024) |
| Horizon Therapeutics plc | $299,227 | 270 | $0 (2023) |
| Horizon Pharma plc | $250,548 | 211 | $0 (2018) |
| Amgen Inc. | $239,154 | 405 | $0 (2024) |
| GlaxoSmithKline, LLC. | $162,181 | 163 | $0 (2024) |
| Celgene Corporation | $78,014 | 176 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $53,308 | 57 | $0 (2024) |
| GENZYME CORPORATION | $51,742 | 92 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $46,949 | 73 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $45,603 | 96 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $218,942 | 335 | Amgen Inc. ($112,477) |
| 2023 | $197,368 | 289 | Amgen Inc. ($57,817) |
| 2022 | $266,830 | 337 | Horizon Therapeutics plc ($113,634) |
| 2021 | $168,274 | 307 | GlaxoSmithKline, LLC. ($62,226) |
| 2020 | $108,316 | 199 | AbbVie Inc. ($42,427) |
| 2019 | $250,335 | 585 | AbbVie, Inc. ($98,800) |
| 2018 | $250,620 | 552 | Horizon Pharma plc ($135,173) |
| 2017 | $220,376 | 516 | Horizon Pharma plc ($115,375) |
All Payment Transactions
3,120 individual payment records from CMS Open Payments — Page 1 of 125
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Travel and Lodging | In-kind items and services | $250.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $9.34 | General |
| Category: Rheumatology | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $8.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Inflammation | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/25/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,550.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/22/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $412.50 | General |
| Category: Inflammation | ||||||
| 11/22/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $29.20 | General |
| 11/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $32.29 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $97.60 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/18/2024 | HOSPIRA, INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $65.05 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,475.00 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 713 | 33,515 | $1.5M | $525,038 |
| 2022 | 34 | 1,373 | 6,611 | $998,798 | $193,890 |
| 2021 | 38 | 1,781 | 7,241 | $955,553 | $211,891 |
| 2020 | 38 | 1,984 | 7,679 | $977,652 | $242,654 |
Total Patients
5,851
Total Services
55,046
Medicare Billing
$1.2M
Procedure Codes
127
All Medicare Procedures & Services
127 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 36 | 5,251 | $566,058 | $177,730 | 31.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 26 | 3,710 | $232,355 | $95,759 | 41.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 34 | 8,600 | $212,066 | $91,459 | 43.1% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 15 | 13,888 | $152,792 | $63,527 | 41.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 224 | 426 | $167,865 | $40,581 | 24.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 841 | $37,189 | $15,754 | 42.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 96 | 182 | $39,394 | $9,222 | 23.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 79 | $34,657 | $8,550 | 24.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $31,611 | $7,790 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 34 | $18,806 | $4,727 | 25.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 30 | 69 | $13,784 | $4,041 | 29.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 93 | $8,585 | $2,151 | 25.1% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 13 | 35 | $5,730 | $1,241 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $4,186 | $1,026 | 24.5% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 29 | 97 | $1,067 | $566.36 | 53.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 48 | $2,141 | $531.37 | 24.8% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 20 | 85 | $935.00 | $382.38 | 40.9% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 15 | 3,798 | $721,620 | $99,065 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 289 | 528 | $110,084 | $48,400 | 44.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 24 | 108 | $47,304 | $10,907 | 23.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 41 | 95 | $22,008 | $5,926 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 33 | $9,449 | $4,722 | 50.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $10,240 | $3,709 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $5,970 | $2,701 | 45.2% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2022 | 22 | 63 | $10,148 | $2,179 | 21.5% |
About Dr. Christopher Parker, DO
Dr. Christopher Parker, DO is a Rheumatology healthcare provider based in West Lake Hills, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912961384.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Parker, DO has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $218,942 received in 2024. These payments were reported across 3,120 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($904,098).
As a Medicare-enrolled provider, Parker has provided services to 5,851 Medicare beneficiaries, totaling 55,046 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 127 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location West Lake Hills, TX
- Active Since 04/13/2006
- Last Updated 03/10/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1912961384
Products in Payments
- KRYSTEXXA (Biological) $349,278
- KRYSTEXXA (Drug) $250,386
- BENLYSTA (Biological) $162,141
- Otezla (Drug) $143,270
- Humira (Biological) $117,930
- RINVOQ (Biological) $112,488
- ACTHAR (Biological) $98,910
- TAVNEOS (Drug) $80,092
- SAPHNELO (Biological) $40,142
- KEVZARA (Biological) $36,944
- Rinvoq (Biological) $34,740
- SKYRIZI (Biological) $32,110
- Tavneos (Drug) $30,238
- RINVOQ (Drug) $20,938
- KEVZARA (Drug) $16,046
- HUMIRA (Biological) $15,019
- Uloric (Drug) $7,648
- SIMPONI ARIA (Biological) $6,416
- LYRICA (Drug) $5,092
- XELJANZ (Drug) $4,537
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.